14.4 OTC Labeling, Hazardous, and Restricted Nonprescription Drugs

Why “it’s only OTC” fails Competency 3.8

Quick Answer: An OTC / nonlegend drug still needs Drug Facts labeling (21 CFR 201.66), a Connecticut nonlegend-drug permit for retail sale (CGS §§ 20-623, 20-624), and whatever extra behind-the-counter or quantity rule applies. Syringes: ten or fewer without a prescription, sold in a licensed pharmacy by a pharmacist or under the pharmacist’s direct supervision (CGS § 21a-65). Plan B (levonorgestrel 1.5 mg) is FDA OTC; pharmacist-prescribed emergency and hormonal contraception is CGS § 20-633k (Chapter 10). Connecticut has not published a general CGS age-18 dextromethorphan sale statute. NIOSH hazardous-drug handling is Chapter 16.2; this section only flags that “nonprescription aisle” does not mean “no occupational hazard.”

Competency 3.8 clusters nonprescription selection, labeling, restricted OTC, and devices. Durham-Humphrey (Chapter 6) split Rx from OTC. This section is what a Hartford pharmacist does at the front end of the store.

Drug Facts — the OTC label that can misbrand the bottle

21 CFR 201.66 requires OTC labeling on the outside container (or the immediate container if there is no outer carton), in this order:

1. Drug Facts (title; later panels say Drug Facts (continued))
2. Active ingredient(s) — established name and amount per dosage unit
3. Purpose(s)
4. Use(s)
5. Warnings (including, as applicable, external/rectal/vaginal use only, “Do not use,” “Ask a doctor,” pregnancy/breast-feeding, Keep out of reach of children)
6. Directions
7. Other information (storage)
8. Inactive ingredients
9. Questions? (optional)

Trade names do not go inside the Drug Facts box. A correctly compounded chemistry with a homemade sticker that omits warnings or claims an unapproved use is misbranded under 21 U.S.C. § 352 — Chapter 6’s labeling problem, now at the cough-and-cold bay. PPPA child-resistant packaging for certain OTCs (iron, some diphenhydramine, etc.) is Chapter 13; do not restock easy-open bulk ibuprofen into an unlabeled bag and call it OTC.

Behind-the-counter is not a third FDA class. Pseudoephedrine remains nonprescription while CMEA restricts access. True OTC sits on the open shelf. Rx-only needs a prescription. A Connecticut exam stem that calls Sudafed “Schedule V” or Plan B “behind-the-counter because all hormones are BTC” is fishing for that three-bin mistake.

Who may sell nonlegend drugs in Connecticut

CGS § 20-623(a): no nonlegend drug may be sold at retail except at a pharmacy, at a store, or in a vending machine owned and operated by a business that holds a DCP permit to sell nonlegend drugs under § 20-624. Application fee $140; renewal $100. P.A. 23-19 authorized OTC vending machines; one premises with several machines still needs one permit, but each machine is covered. RCSA § 20-576-31 still says no nonlegend drug shall be sold in a vending machine. That regulation has not been rewritten to match the statute. Current § 20-623 controls.

CGS § 20-610 still keeps certain articles out of ordinary retail even when a shopper thinks they are “just OTC”: injectable or ingestible antibiotics, injectable biologicals, systemic sulfonamides, injectable or ingestible corticosteroids, and camphorated tincture of opium may not be sold at retail except in a pharmacy (or the narrow hospital-employee/retiree path). A gas-station nonlegend permit is not a license to sell injectable dexamethasone.

CGS § 21a-272 exempts tiny amounts of listed Schedule V opium cough mixtures from the prescription requirement, with a handwritten purchaser record, a 48-hour quantity cap, and a pharmacy label. That is a CV exempt preparation, not Drug Facts ibuprofen.

Syringes, Plan B, dextromethorphan, hazardous teasers

Needles and syringes — CGS § 21a-65 (regulations under § 21a-66):

• A licensed manufacturer or wholesaler may sell only to listed professional, institutional, laboratory, farm, industrial, or syringe services program recipients.
• No licensed pharmacist shall sell, and no person shall buy, a hypodermic needle or syringe except upon a prescription in a quantity greater than ten. Keep that prescription not less than three years.
• Ten or fewer without a prescription may be provided or sold at retail only (1) by a § 20-594 pharmacy, and only by a licensed pharmacist or under the pharmacist’s direct supervision, (2) by a syringe services program (CGS § 19a-124), or (3) by a health-care facility or licensed practitioner for their own patients.

A clerk tossing a 100-count insulin-syringe box across a checkout lane without a prescription is the wrong quantity and the wrong person. Ten U-100 syringes sold by the pharmacist to a person who injects drugs, without a prescription, is the harm-reduction path the statute wrote.

Emergency contraception versus pharmacist prescribing:

• Levonorgestrel 1.5 mg (Plan B One-Step and generics) is FDA nonprescription. There is no federal age-of-sale restriction on the current Drug Facts carton. Keep it where theft and counseling needs dictate; that is practice, not a CGS lockbox statute.
• Ulipristal acetate (ella) remains prescription-only.
• CGS § 20-633k lets a trained pharmacist prescribe emergency or hormonal contraceptives after screening — including a product that is already OTC, so insurance can be billed, and including methods that are not OTC (pill, patch, ring, injection). Implants and IUDs are out of scope. Full protocol is Chapter 10. This chapter’s only job is: OTC Plan B did not repeal § 20-633k, and § 20-633k is not “Plan B is now Rx.”

Dextromethorphan: many states enacted an age-18 OTC DXM sale law. Connecticut has not published a general CGS age-of-sale statute for dextromethorphan cough products. Do not invent an 18-and-older Connecticut DXM number. A valid prescription can always be filled. A chain that cards for DXM is running store policy, not a published CGS floor. If a later public act appears, DCP will post it; until then, say not published.

NIOSH / USP <800> teaser: The NIOSH List of Hazardous Drugs in Healthcare Settings, 2024 (Publication 2025-103) is now two tables: Table 1 (manufacturer special handling information and/or NTP/IARC carcinogenicity) and Table 2 (other NIOSH-criteria drugs). Community pharmacies still count, pour, and sometimes split methotrexate, finasteride, tamoxifen, valproic acid, and antineoplastic tablets. USP <800> containment, assessment of risk, and PPE are Chapter 16.2. Here: an “OTC aisle” colchicine bottle or a nonprescription estradiol cream does not get a free pass from hazardous-drug identification, and you do not crush a NIOSH tablet on an open counting tray because the patient asked for a powder. Counting intact finished dosage forms may follow an assessment of risk; manipulation of Table 1 antineoplastics does not.

Realistic Connecticut scenario

A Waterbury grocery with a § 20-624 permit sells acetaminophen from an aisle endcap; Drug Facts is intact. That is lawful nonlegend retail. The same grocery cannot sell injectable ceftriaxone under § 20-610. A pharmacy technician, not under pharmacist supervision, sells a box of 40 insulin syringes with no prescription: § 21a-65 failed on quantity and supervision. Ten syringes sold by the pharmacist, no Rx, is lawful.

A 17-year-old asks for Plan B. The carton is OTC; there is no CGS age lock on levonorgestrel 1.5 mg. If she instead wants a pharmacist-prescribed 12-month hormonal contraceptive, that is § 20-633k and Chapter 10, not Drug Facts. A parent demanding the pharmacist refuse OTC DXM “because Connecticut says 18” is quoting another state’s statute unless the stem supplies a Connecticut public act.

Official anchors

• 21 CFR 201.66 — OTC Drug Facts format and order.
• CGS § 20-623 / § 20-624 — nonlegend retail sale and permit, including vending machines.
• CGS § 21a-65 — hypodermic needles and syringes, ten-or-fewer OTC path.
• CGS § 20-633k — pharmacist prescribing of emergency and hormonal contraceptives (detail in Chapter 10).
• NIOSH List of Hazardous Drugs, 2024 — Table 1 / Table 2; USP <800> handling in Chapter 16.2.